Zacks: Centogene N.V. (NASDAQ:CNTG) Given Average Rating of “Strong Buy” by Brokerages

Shares of Centogene N.V. (NASDAQ:CNTG) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Zacks has also given Centogene an industry rank of 44 out of 255 based on the ratings given to its competitors.

A number of equities analysts have recently commented on CNTG shares. BTIG Research began coverage on shares of Centogene in a research note on Monday. They set a “buy” rating and a $18.00 price objective for the company. Robert W. Baird assumed coverage on Centogene in a research report on Tuesday. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Evercore ISI assumed coverage on Centogene in a research note on Monday. They set an “outperform” rating and a $17.00 target price for the company.

Shares of CNTG stock traded down $0.05 during trading hours on Tuesday, hitting $12.20. 91,166 shares of the company were exchanged, compared to its average volume of 58,616. Centogene has a 52 week low of $11.81 and a 52 week high of $15.59.

About Centogene

Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.

Recommended Story: How mutual funds make money

Get a free copy of the Zacks research report on Centogene (CNTG)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with's FREE daily email newsletter.